Document is current
Any future updates will be listed below
-
Authors
Vilor-Tejedor, Natalia http://orcid.org/0000-0003-4935-6721
Ciampa, Iacopo
Operto, Grégory
Falcón, Carles
Suárez-Calvet, Marc
Crous-Bou, Marta
Shekari, Mahnaz
Arenaza-Urquijo, Eider M.
Milà-Alomà, Marta
Grau-Rivera, Oriol
Minguillon, Carolina
Kollmorgen, Gwendlyn
Zetterberg, Henrik
Blennow, Kaj
Guigo, Roderic
Molinuevo, José Luis http://orcid.org/0000-0003-0485-6001
Gispert, Juan Domingo http://orcid.org/0000-0002-6155-0642
,
Beteta, Annabella
Brugulat, Anna
Cacciaglia, Raffaele
Cañas, Alba
Deulofeu, Carme
Cumplido, Irene
Dominguez, Ruth
Emilio, Maria
Fauria, Karine
Fuentes, Sherezade
Hernandez, Laura
Huesa, Gema
Huguet, Jordi
Marne, Paula
Menchón, Tania
Polo, Albina
Pradas, Sandra
Rodriguez-Fernandez, Blanca
Sala-Vila, Aleix
Sánchez-Benavides, Gonzalo
Salvadó, Gemma
Soteras, Anna
Vilanova, Marc
-
Funding
Funding for this research was provided by:
La Caixa (LCF/PR/GN17/50300004)
TriBEKa Imaging Platform Project (TriBEKa-17-519007)
Health Research and Innovation Strategic Plan (SLT002/16/00201)
Ministry of Business and Knowledge of the Catalan Government (2017-SGR-892)
Juan de la Cierva Programme (FJC2018-038085-I)
H2020 Marie Skłodowska-Curie Actions (752310)
Instituto de Salud Carlos III (PI19/00155)
Juan de la Cierva Programme Grant (IJC2018-037478-I)
Spanish Ministry of Science (RYC2018-026053-I, FJCI-2017-33437)
Spanish Ministry of Science and Innovation (RYC-2013-13054)
Swedish Research Council (#2017-00915, 2018-02532)
Alzheimer's Drug Discovery Foundation (RDAPB-201809-2016615, 201809-2016862)
Swedish Alzheimer Foundation (AF-742881)
Hjärnfonden (FO2017-0243)
ALF-agreement (ALFGBG-715986, ALFGBG-720931)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
European Research Council (681712)
- License Information
-
More Information
Article History
Received: 30 September 2020
Accepted: 21 July 2021
First Online: 5 August 2021
Declarations
:
: The study was conducted following the directives of Spanish Law 14/2007, of 3rd July, on Biomedical Research (Ley 14/2007 de Investigación Biomédica). Study protocols were approved by the Clinical Research Ethics Committee “Parc de Salut Mar”, Barcelona. All participants accepted the study procedures by signing the study’s informed consent form.
: Not applicable.
: GK is a full-time employee of Roche Diagnostics GmbH. The remaining authors declare that they have no conflict of interest. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen;and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. JLM has served/serves as a consultant or at advisory boards for the following for-profit companies or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, ProMIS Neurosciences. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The other co-authors declare that they have no competing interests.
